Respiratory Syncytial Virus Infection (RSV) Vaccines

High-risk older adult RSV vaccine program

• The RSV vaccines available for the 2024-25 season are Arexvy (GSK) and Abrysvo (Pfizer).

• The publicly funded High-Risk Older Adult program includes individuals who are aged 60 years and older and are also:

o residents of long-term care homes, Elder Care Lodges, or retirement homes

o patients in hospital receiving alternate level of care (ALC) including similar settings (for example, complex continuing care, hospital transitional programs)

o patients receiving hemodialysis or peritoneal dialysis

o recipients of solid organ or hematopoietic stem cell transplants

o individuals experiencing homelessness o individuals who identify as First Nations, Inuit, or Métis

• Eligible older adults will be able to receive a single publicly funded dose of either Arexvy or Abrysvo if they have not previously received a dose

• Re-immunization is not required for individuals who were vaccinated last year; studies indicate that the RSV vaccine offers multi-year protection.

• Individuals 60 years of age and older who do not qualify for a publicly funded dose of the RSV vaccine can purchase the vaccine with a prescription through their local pharmacy.

Publicly Funded RSV vaccine is not available in pharmacy.